Rein Therapeutics Inc. (RNTX) は上場企業です ヘルスケア セクターの Medical - Pharmaceuticals 業界で事業展開. 本社所在地は Austin, TX, アメリカ. 現CEOは James Brian Windsor.
RNTX を有する IPO日 2017-06-29, 11 名の正社員, に上場 NASDAQ Global Market, 時価総額 $45.7M.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
